nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—Gefitinib—Lapatinib—breast cancer	0.253	1	CrCrCtD
Vandetanib—ERBB3—breast cancer	0.0542	0.19	CbGaD
Vandetanib—EGFR—Lapatinib—breast cancer	0.0501	0.218	CbGbCtD
Vandetanib—ABL1—breast cancer	0.04	0.14	CbGaD
Vandetanib—FMO1—Tamoxifen—breast cancer	0.0365	0.159	CbGbCtD
Vandetanib—SRC—breast cancer	0.0362	0.127	CbGaD
Vandetanib—KDR—breast cancer	0.034	0.119	CbGaD
Vandetanib—ABCC1—breast cancer	0.0337	0.118	CbGaD
Vandetanib—VEGFA—breast cancer	0.0288	0.101	CbGaD
Vandetanib—EGFR—breast cancer	0.0243	0.0851	CbGaD
Vandetanib—FMO3—Tamoxifen—breast cancer	0.0228	0.0995	CbGbCtD
Vandetanib—ABCG2—breast cancer	0.0178	0.0622	CbGaD
Vandetanib—EGFR—Docetaxel—breast cancer	0.0141	0.0615	CbGbCtD
Vandetanib—ABCC1—Idarubicin—breast cancer	0.014	0.0612	CbGbCtD
Vandetanib—CYP3A4—breast cancer	0.00888	0.0311	CbGaD
Vandetanib—ALB—breast cancer	0.00774	0.0271	CbGaD
Vandetanib—ABCC1—Mitoxantrone—breast cancer	0.00604	0.0263	CbGbCtD
Vandetanib—ABCC1—Epirubicin—breast cancer	0.00489	0.0213	CbGbCtD
Vandetanib—ABCC1—Paclitaxel—breast cancer	0.00482	0.021	CbGbCtD
Vandetanib—ABCC1—Irinotecan—breast cancer	0.00475	0.0207	CbGbCtD
Vandetanib—ABCC1—Vinblastine—breast cancer	0.00423	0.0184	CbGbCtD
Vandetanib—ABCG2—Tamoxifen—breast cancer	0.00414	0.0181	CbGbCtD
Vandetanib—ABCG2—Mitoxantrone—breast cancer	0.00404	0.0176	CbGbCtD
Vandetanib—CYP3A4—Exemestane—breast cancer	0.00354	0.0154	CbGbCtD
Vandetanib—ABCC1—Docetaxel—breast cancer	0.00348	0.0152	CbGbCtD
Vandetanib—ABCG2—Paclitaxel—breast cancer	0.00323	0.0141	CbGbCtD
Vandetanib—ABCG2—Irinotecan—breast cancer	0.00318	0.0139	CbGbCtD
Vandetanib—ABCG2—Fluorouracil—breast cancer	0.00305	0.0133	CbGbCtD
Vandetanib—ABCG2—Carboplatin—breast cancer	0.00304	0.0132	CbGbCtD
Vandetanib—CYP3A4—Letrozole—breast cancer	0.00301	0.0131	CbGbCtD
Vandetanib—CYP3A4—Anastrozole—breast cancer	0.00268	0.0117	CbGbCtD
Vandetanib—ABCC1—Doxorubicin—breast cancer	0.0026	0.0113	CbGbCtD
Vandetanib—ABCC1—Methotrexate—breast cancer	0.00252	0.011	CbGbCtD
Vandetanib—CYP3A4—Toremifene—breast cancer	0.00245	0.0107	CbGbCtD
Vandetanib—ABCG2—Docetaxel—breast cancer	0.00233	0.0102	CbGbCtD
Vandetanib—CYP3A4—Fulvestrant—breast cancer	0.00228	0.00993	CbGbCtD
Vandetanib—ALB—Irinotecan—breast cancer	0.00219	0.00956	CbGbCtD
Vandetanib—ALB—Fluorouracil—breast cancer	0.0021	0.00917	CbGbCtD
Vandetanib—CYP3A4—Thiotepa—breast cancer	0.00203	0.00885	CbGbCtD
Vandetanib—CYP3A4—Ixabepilone—breast cancer	0.00186	0.00809	CbGbCtD
Vandetanib—CYP3A4—Lapatinib—breast cancer	0.00179	0.00779	CbGbCtD
Vandetanib—ABCG2—Doxorubicin—breast cancer	0.00174	0.00757	CbGbCtD
Vandetanib—ABCG2—Methotrexate—breast cancer	0.00168	0.00734	CbGbCtD
Vandetanib—CYP3A4—Raloxifene—breast cancer	0.00135	0.0059	CbGbCtD
Vandetanib—ALB—Methotrexate—breast cancer	0.00116	0.00506	CbGbCtD
Vandetanib—CYP3A4—Vinorelbine—breast cancer	0.000992	0.00432	CbGbCtD
Vandetanib—CYP3A4—Tamoxifen—breast cancer	0.000895	0.0039	CbGbCtD
Vandetanib—CYP3A4—Mitoxantrone—breast cancer	0.000873	0.0038	CbGbCtD
Vandetanib—CYP3A4—Paclitaxel—breast cancer	0.000697	0.00304	CbGbCtD
Vandetanib—CYP3A4—Irinotecan—breast cancer	0.000687	0.003	CbGbCtD
Vandetanib—CYP3A4—Vinblastine—breast cancer	0.000611	0.00266	CbGbCtD
Vandetanib—CYP3A4—Docetaxel—breast cancer	0.000504	0.0022	CbGbCtD
Vandetanib—CYP3A4—Doxorubicin—breast cancer	0.000375	0.00164	CbGbCtD
Vandetanib—MKNK1—Estradiol—Fulvestrant—breast cancer	0.000339	0.204	CbGdCrCtD
Vandetanib—Afatinib—ERBB4—breast cancer	0.000302	0.0942	CrCbGaD
Vandetanib—Afatinib—ERBB2—breast cancer	0.000223	0.0696	CrCbGaD
Vandetanib—Bosutinib—BMPR2—breast cancer	0.000223	0.0696	CrCbGaD
Vandetanib—Bosutinib—EPHB4—breast cancer	0.000223	0.0696	CrCbGaD
Vandetanib—Bosutinib—CDK2—breast cancer	0.000204	0.0637	CrCbGaD
Vandetanib—VEGFA—Estradiol—Fulvestrant—breast cancer	0.000195	0.117	CbGdCrCtD
Vandetanib—Afatinib—ABL1—breast cancer	0.000173	0.0541	CrCbGaD
Vandetanib—VEGFA—uterus—breast cancer	0.000173	0.00363	CbGeAlD
Vandetanib—FLT3—female reproductive system—breast cancer	0.000173	0.00362	CbGeAlD
Vandetanib—EPHA5—endocrine gland—breast cancer	0.000172	0.0036	CbGeAlD
Vandetanib—TYRO3—endocrine gland—breast cancer	0.000172	0.0036	CbGeAlD
Vandetanib—LYN—endocrine gland—breast cancer	0.000171	0.00358	CbGeAlD
Vandetanib—FLT4—adipose tissue—breast cancer	0.000171	0.00358	CbGeAlD
Vandetanib—RIPK2—pituitary gland—breast cancer	0.00017	0.00357	CbGeAlD
Vandetanib—KDR—embryo—breast cancer	0.00017	0.00356	CbGeAlD
Vandetanib—VEGFA—pituitary gland—breast cancer	0.00017	0.00356	CbGeAlD
Vandetanib—TEK—epithelium—breast cancer	0.00017	0.00356	CbGeAlD
Vandetanib—RIPK2—adipose tissue—breast cancer	0.00017	0.00356	CbGeAlD
Vandetanib—VEGFA—adipose tissue—breast cancer	0.000169	0.00355	CbGeAlD
Vandetanib—MKNK1—endometrium—breast cancer	0.000169	0.00355	CbGeAlD
Vandetanib—STK35—female reproductive system—breast cancer	0.000169	0.00355	CbGeAlD
Vandetanib—FMO1—pituitary gland—breast cancer	0.000169	0.00354	CbGeAlD
Vandetanib—FLT3—adrenal gland—breast cancer	0.000168	0.00353	CbGeAlD
Vandetanib—BMPR1B—endocrine gland—breast cancer	0.000168	0.00353	CbGeAlD
Vandetanib—FMO1—adipose tissue—breast cancer	0.000168	0.00353	CbGeAlD
Vandetanib—FGR—endometrium—breast cancer	0.000167	0.0035	CbGeAlD
Vandetanib—AXL—endometrium—breast cancer	0.000166	0.00349	CbGeAlD
Vandetanib—IRAK4—pituitary gland—breast cancer	0.000166	0.00349	CbGeAlD
Vandetanib—ERBB3—uterus—breast cancer	0.000166	0.00348	CbGeAlD
Vandetanib—IRAK4—adipose tissue—breast cancer	0.000166	0.00347	CbGeAlD
Vandetanib—FYN—skin of body—breast cancer	0.000165	0.00346	CbGeAlD
Vandetanib—STK35—adrenal gland—breast cancer	0.000165	0.00346	CbGeAlD
Vandetanib—FLT3—bone marrow—breast cancer	0.000163	0.00342	CbGeAlD
Vandetanib—ERBB3—adipose tissue—breast cancer	0.000162	0.0034	CbGeAlD
Vandetanib—BLK—lymph node—breast cancer	0.000162	0.0034	CbGeAlD
Vandetanib—ABL2—adrenal gland—breast cancer	0.000161	0.00337	CbGeAlD
Vandetanib—SLK—endometrium—breast cancer	0.00016	0.00336	CbGeAlD
Vandetanib—LTK—lymph node—breast cancer	0.00016	0.00336	CbGeAlD
Vandetanib—PLK4—Topotecan—Irinotecan—breast cancer	0.000159	0.0961	CbGdCrCtD
Vandetanib—ABL1—nipple—breast cancer	0.000159	0.00333	CbGeAlD
Vandetanib—FLT3—female gonad—breast cancer	0.000157	0.00329	CbGeAlD
Vandetanib—EGFR—adrenal gland—breast cancer	0.000157	0.00329	CbGeAlD
Vandetanib—FLT4—female reproductive system—breast cancer	0.000157	0.00329	CbGeAlD
Vandetanib—RIPK2—female reproductive system—breast cancer	0.000156	0.00327	CbGeAlD
Vandetanib—FYN—endometrium—breast cancer	0.000156	0.00327	CbGeAlD
Vandetanib—EPHB6—skin of body—breast cancer	0.000154	0.00324	CbGeAlD
Vandetanib—LCK—uterus—breast cancer	0.000154	0.00323	CbGeAlD
Vandetanib—STK35—female gonad—breast cancer	0.000154	0.00323	CbGeAlD
Vandetanib—AXL—uterus—breast cancer	0.000153	0.00322	CbGeAlD
Vandetanib—MKNK1—pituitary gland—breast cancer	0.000153	0.00321	CbGeAlD
Vandetanib—FLT4—adrenal gland—breast cancer	0.000153	0.00321	CbGeAlD
Vandetanib—MKNK1—adipose tissue—breast cancer	0.000152	0.0032	CbGeAlD
Vandetanib—TEK—endometrium—breast cancer	0.000152	0.00319	CbGeAlD
Vandetanib—MAP4K5—endometrium—breast cancer	0.000152	0.00319	CbGeAlD
Vandetanib—RIPK2—adrenal gland—breast cancer	0.000152	0.00319	CbGeAlD
Vandetanib—VEGFA—adrenal gland—breast cancer	0.000152	0.00318	CbGeAlD
Vandetanib—FGR—pituitary gland—breast cancer	0.000151	0.00317	CbGeAlD
Vandetanib—RET—pituitary gland—breast cancer	0.000151	0.00317	CbGeAlD
Vandetanib—FMO1—adrenal gland—breast cancer	0.000151	0.00316	CbGeAlD
Vandetanib—SRC—epithelium—breast cancer	0.000151	0.00316	CbGeAlD
Vandetanib—AXL—pituitary gland—breast cancer	0.000151	0.00316	CbGeAlD
Vandetanib—LCK—adipose tissue—breast cancer	0.000151	0.00316	CbGeAlD
Vandetanib—FGR—adipose tissue—breast cancer	0.000151	0.00316	CbGeAlD
Vandetanib—AXL—adipose tissue—breast cancer	0.00015	0.00314	CbGeAlD
Vandetanib—ABL2—female gonad—breast cancer	0.00015	0.00314	CbGeAlD
Vandetanib—ERBB3—female reproductive system—breast cancer	0.000149	0.00313	CbGeAlD
Vandetanib—IRAK4—adrenal gland—breast cancer	0.000149	0.00312	CbGeAlD
Vandetanib—FLT4—bone marrow—breast cancer	0.000148	0.0031	CbGeAlD
Vandetanib—SLK—uterus—breast cancer	0.000148	0.0031	CbGeAlD
Vandetanib—RIPK2—bone marrow—breast cancer	0.000147	0.00309	CbGeAlD
Vandetanib—PDGFRB—embryo—breast cancer	0.000147	0.00309	CbGeAlD
Vandetanib—VEGFA—bone marrow—breast cancer	0.000147	0.00308	CbGeAlD
Vandetanib—EGFR—female gonad—breast cancer	0.000146	0.00307	CbGeAlD
Vandetanib—FLT3—endocrine gland—breast cancer	0.000146	0.00306	CbGeAlD
Vandetanib—FMO3—pituitary gland—breast cancer	0.000146	0.00306	CbGeAlD
Vandetanib—EPHB6—endometrium—breast cancer	0.000145	0.00305	CbGeAlD
Vandetanib—FMO3—adipose tissue—breast cancer	0.000145	0.00305	CbGeAlD
Vandetanib—SLK—pituitary gland—breast cancer	0.000145	0.00304	CbGeAlD
Vandetanib—SLK—adipose tissue—breast cancer	0.000144	0.00303	CbGeAlD
Vandetanib—IRAK4—bone marrow—breast cancer	0.000144	0.00301	CbGeAlD
Vandetanib—FYN—uterus—breast cancer	0.000143	0.00301	CbGeAlD
Vandetanib—SRC—skin of body—breast cancer	0.000143	0.00301	CbGeAlD
Vandetanib—STK35—endocrine gland—breast cancer	0.000143	0.003	CbGeAlD
Vandetanib—FLT4—female gonad—breast cancer	0.000143	0.00299	CbGeAlD
Vandetanib—RIPK2—female gonad—breast cancer	0.000142	0.00297	CbGeAlD
Vandetanib—VEGFA—female gonad—breast cancer	0.000141	0.00297	CbGeAlD
Vandetanib—FYN—pituitary gland—breast cancer	0.000141	0.00296	CbGeAlD
Vandetanib—FMO1—female gonad—breast cancer	0.000141	0.00295	CbGeAlD
Vandetanib—YES1—endometrium—breast cancer	0.000141	0.00295	CbGeAlD
Vandetanib—FYN—adipose tissue—breast cancer	0.00014	0.00294	CbGeAlD
Vandetanib—TEK—uterus—breast cancer	0.00014	0.00294	CbGeAlD
Vandetanib—MAP4K5—uterus—breast cancer	0.00014	0.00294	CbGeAlD
Vandetanib—MKNK1—female reproductive system—breast cancer	0.00014	0.00294	CbGeAlD
Vandetanib—KDR—epithelium—breast cancer	0.000139	0.00291	CbGeAlD
Vandetanib—IRAK4—female gonad—breast cancer	0.000139	0.00291	CbGeAlD
Vandetanib—FGR—female reproductive system—breast cancer	0.000138	0.0029	CbGeAlD
Vandetanib—AXL—female reproductive system—breast cancer	0.000138	0.00289	CbGeAlD
Vandetanib—MAP4K5—pituitary gland—breast cancer	0.000138	0.00289	CbGeAlD
Vandetanib—TEK—pituitary gland—breast cancer	0.000138	0.00289	CbGeAlD
Vandetanib—MAP4K5—adipose tissue—breast cancer	0.000137	0.00288	CbGeAlD
Vandetanib—TEK—adipose tissue—breast cancer	0.000137	0.00288	CbGeAlD
Vandetanib—MKNK1—adrenal gland—breast cancer	0.000137	0.00287	CbGeAlD
Vandetanib—ERBB3—female gonad—breast cancer	0.000136	0.00285	CbGeAlD
Vandetanib—FGR—adrenal gland—breast cancer	0.000135	0.00283	CbGeAlD
Vandetanib—LCK—adrenal gland—breast cancer	0.000135	0.00283	CbGeAlD
Vandetanib—RET—adrenal gland—breast cancer	0.000135	0.00283	CbGeAlD
Vandetanib—AXL—adrenal gland—breast cancer	0.000135	0.00282	CbGeAlD
Vandetanib—ABL1—Topotecan—Irinotecan—breast cancer	0.000134	0.0808	CbGdCrCtD
Vandetanib—FLT4—endocrine gland—breast cancer	0.000133	0.00278	CbGeAlD
Vandetanib—MKNK1—bone marrow—breast cancer	0.000132	0.00277	CbGeAlD
Vandetanib—RIPK2—endocrine gland—breast cancer	0.000132	0.00277	CbGeAlD
Vandetanib—EPHB6—pituitary gland—breast cancer	0.000132	0.00276	CbGeAlD
Vandetanib—Bosutinib—ERBB4—breast cancer	0.000131	0.041	CrCbGaD
Vandetanib—ABL1—embryo—breast cancer	0.000131	0.00275	CbGeAlD
Vandetanib—EPHB6—adipose tissue—breast cancer	0.000131	0.00275	CbGeAlD
Vandetanib—FMO1—endocrine gland—breast cancer	0.000131	0.00274	CbGeAlD
Vandetanib—FGR—bone marrow—breast cancer	0.000131	0.00274	CbGeAlD
Vandetanib—LCK—bone marrow—breast cancer	0.000131	0.00274	CbGeAlD
Vandetanib—FMO3—adrenal gland—breast cancer	0.00013	0.00274	CbGeAlD
Vandetanib—YES1—uterus—breast cancer	0.00013	0.00272	CbGeAlD
Vandetanib—SLK—adrenal gland—breast cancer	0.000129	0.00272	CbGeAlD
Vandetanib—FYN—female reproductive system—breast cancer	0.000129	0.00271	CbGeAlD
Vandetanib—STK10—uterus—breast cancer	0.000128	0.00269	CbGeAlD
Vandetanib—MKNK1—female gonad—breast cancer	0.000127	0.00267	CbGeAlD
Vandetanib—YES1—pituitary gland—breast cancer	0.000127	0.00267	CbGeAlD
Vandetanib—YES1—adipose tissue—breast cancer	0.000127	0.00266	CbGeAlD
Vandetanib—PLK4—lymph node—breast cancer	0.000126	0.00265	CbGeAlD
Vandetanib—ERBB3—endocrine gland—breast cancer	0.000126	0.00265	CbGeAlD
Vandetanib—MAP4K5—female reproductive system—breast cancer	0.000126	0.00264	CbGeAlD
Vandetanib—TEK—female reproductive system—breast cancer	0.000126	0.00264	CbGeAlD
Vandetanib—FGR—female gonad—breast cancer	0.000126	0.00264	CbGeAlD
Vandetanib—LCK—female gonad—breast cancer	0.000126	0.00264	CbGeAlD
Vandetanib—FYN—adrenal gland—breast cancer	0.000126	0.00264	CbGeAlD
Vandetanib—STK10—adipose tissue—breast cancer	0.000126	0.00263	CbGeAlD
Vandetanib—AXL—female gonad—breast cancer	0.000125	0.00263	CbGeAlD
Vandetanib—SLK—bone marrow—breast cancer	0.000125	0.00263	CbGeAlD
Vandetanib—KDR—endometrium—breast cancer	0.000124	0.00261	CbGeAlD
Vandetanib—MAP2K5—endometrium—breast cancer	0.000124	0.00261	CbGeAlD
Vandetanib—TEK—adrenal gland—breast cancer	0.000123	0.00258	CbGeAlD
Vandetanib—MAP4K5—adrenal gland—breast cancer	0.000123	0.00258	CbGeAlD
Vandetanib—Erlotinib—ABL1—breast cancer	0.000122	0.0382	CrCbGaD
Vandetanib—SRC—adipose tissue—breast cancer	0.000122	0.00256	CbGeAlD
Vandetanib—FYN—bone marrow—breast cancer	0.000122	0.00255	CbGeAlD
Vandetanib—ABCC1—nipple—breast cancer	0.000121	0.00254	CbGeAlD
Vandetanib—SLK—female gonad—breast cancer	0.000121	0.00253	CbGeAlD
Vandetanib—PDGFRB—epithelium—breast cancer	0.00012	0.00252	CbGeAlD
Vandetanib—MAP4K5—bone marrow—breast cancer	0.000119	0.0025	CbGeAlD
Vandetanib—MKNK1—endocrine gland—breast cancer	0.000119	0.00249	CbGeAlD
Vandetanib—EPHB6—adrenal gland—breast cancer	0.000118	0.00247	CbGeAlD
Vandetanib—FYN—female gonad—breast cancer	0.000117	0.00246	CbGeAlD
Vandetanib—FGR—endocrine gland—breast cancer	0.000117	0.00246	CbGeAlD
Vandetanib—RET—endocrine gland—breast cancer	0.000117	0.00246	CbGeAlD
Vandetanib—Gefitinib—CHEK2—breast cancer	0.000117	0.0364	CrCbGaD
Vandetanib—AXL—endocrine gland—breast cancer	0.000117	0.00245	CbGeAlD
Vandetanib—YES1—female reproductive system—breast cancer	0.000116	0.00244	CbGeAlD
Vandetanib—BMPR1B—lymph node—breast cancer	0.000116	0.00244	CbGeAlD
Vandetanib—STK10—female reproductive system—breast cancer	0.000115	0.00242	CbGeAlD
Vandetanib—Bosutinib—CHEK2—breast cancer	0.000115	0.0359	CrCbGaD
Vandetanib—MAP4K5—female gonad—breast cancer	0.000115	0.00241	CbGeAlD
Vandetanib—TEK—female gonad—breast cancer	0.000115	0.00241	CbGeAlD
Vandetanib—KDR—uterus—breast cancer	0.000115	0.0024	CbGeAlD
Vandetanib—PDGFRB—skin of body—breast cancer	0.000114	0.00239	CbGeAlD
Vandetanib—YES1—adrenal gland—breast cancer	0.000114	0.00238	CbGeAlD
Vandetanib—FMO3—endocrine gland—breast cancer	0.000113	0.00237	CbGeAlD
Vandetanib—STK10—adrenal gland—breast cancer	0.000113	0.00236	CbGeAlD
Vandetanib—MAP2K5—pituitary gland—breast cancer	0.000113	0.00236	CbGeAlD
Vandetanib—KDR—pituitary gland—breast cancer	0.000113	0.00236	CbGeAlD
Vandetanib—KDR—adipose tissue—breast cancer	0.000112	0.00235	CbGeAlD
Vandetanib—MAP2K5—adipose tissue—breast cancer	0.000112	0.00235	CbGeAlD
Vandetanib—SRC—female reproductive system—breast cancer	0.000112	0.00235	CbGeAlD
Vandetanib—YES1—bone marrow—breast cancer	0.00011	0.00231	CbGeAlD
Vandetanib—EPHB6—female gonad—breast cancer	0.00011	0.0023	CbGeAlD
Vandetanib—SRC—adrenal gland—breast cancer	0.000109	0.00229	CbGeAlD
Vandetanib—FYN—endocrine gland—breast cancer	0.000109	0.00229	CbGeAlD
Vandetanib—STK10—bone marrow—breast cancer	0.000109	0.00228	CbGeAlD
Vandetanib—PDGFRB—endometrium—breast cancer	0.000108	0.00226	CbGeAlD
Vandetanib—MAP4K5—endocrine gland—breast cancer	0.000107	0.00224	CbGeAlD
Vandetanib—TEK—endocrine gland—breast cancer	0.000107	0.00224	CbGeAlD
Vandetanib—YES1—female gonad—breast cancer	0.000106	0.00222	CbGeAlD
Vandetanib—Afatinib—EGFR—breast cancer	0.000105	0.0329	CrCbGaD
Vandetanib—STK10—female gonad—breast cancer	0.000105	0.0022	CbGeAlD
Vandetanib—Gefitinib—ERBB3—breast cancer	0.000104	0.0325	CrCbGaD
Vandetanib—KDR—female reproductive system—breast cancer	0.000103	0.00216	CbGeAlD
Vandetanib—MAP2K5—female reproductive system—breast cancer	0.000103	0.00216	CbGeAlD
Vandetanib—Bosutinib—ALK—breast cancer	0.000102	0.032	CrCbGaD
Vandetanib—Bosutinib—ERBB3—breast cancer	0.000102	0.032	CrCbGaD
Vandetanib—SRC—female gonad—breast cancer	0.000102	0.00214	CbGeAlD
Vandetanib—ABL1—skin of body—breast cancer	0.000102	0.00213	CbGeAlD
Vandetanib—ORM1—endometrium—breast cancer	0.000101	0.00212	CbGeAlD
Vandetanib—FLT3—lymph node—breast cancer	0.000101	0.00212	CbGeAlD
Vandetanib—KDR—adrenal gland—breast cancer	0.000101	0.00211	CbGeAlD
Vandetanib—MAP2K5—adrenal gland—breast cancer	0.000101	0.00211	CbGeAlD
Vandetanib—PDGFRB—uterus—breast cancer	9.92e-05	0.00208	CbGeAlD
Vandetanib—STK35—lymph node—breast cancer	9.89e-05	0.00207	CbGeAlD
Vandetanib—YES1—endocrine gland—breast cancer	9.85e-05	0.00207	CbGeAlD
Vandetanib—STK10—endocrine gland—breast cancer	9.76e-05	0.00205	CbGeAlD
Vandetanib—PDGFRB—pituitary gland—breast cancer	9.74e-05	0.00204	CbGeAlD
Vandetanib—KDR—bone marrow—breast cancer	9.73e-05	0.00204	CbGeAlD
Vandetanib—Bosutinib—CSF1R—breast cancer	9.71e-05	0.0303	CrCbGaD
Vandetanib—PDGFRB—adipose tissue—breast cancer	9.7e-05	0.00203	CbGeAlD
Vandetanib—ABL2—lymph node—breast cancer	9.64e-05	0.00202	CbGeAlD
Vandetanib—ABL1—endometrium—breast cancer	9.59e-05	0.00201	CbGeAlD
Vandetanib—SRC—endocrine gland—breast cancer	9.48e-05	0.00199	CbGeAlD
Vandetanib—EGFR—lymph node—breast cancer	9.41e-05	0.00197	CbGeAlD
Vandetanib—KDR—female gonad—breast cancer	9.37e-05	0.00197	CbGeAlD
Vandetanib—MAP2K5—female gonad—breast cancer	9.37e-05	0.00197	CbGeAlD
Vandetanib—FLT4—lymph node—breast cancer	9.17e-05	0.00192	CbGeAlD
Vandetanib—RIPK2—lymph node—breast cancer	9.12e-05	0.00191	CbGeAlD
Vandetanib—VEGFA—lymph node—breast cancer	9.09e-05	0.00191	CbGeAlD
Vandetanib—FMO1—lymph node—breast cancer	9.05e-05	0.0019	CbGeAlD
Vandetanib—PDGFRB—female reproductive system—breast cancer	8.92e-05	0.00187	CbGeAlD
Vandetanib—IRAK4—lymph node—breast cancer	8.91e-05	0.00187	CbGeAlD
Vandetanib—ABL1—uterus—breast cancer	8.84e-05	0.00185	CbGeAlD
Vandetanib—ERBB3—lymph node—breast cancer	8.73e-05	0.00183	CbGeAlD
Vandetanib—MAP2K5—endocrine gland—breast cancer	8.72e-05	0.00183	CbGeAlD
Vandetanib—KDR—endocrine gland—breast cancer	8.72e-05	0.00183	CbGeAlD
Vandetanib—PDGFRB—adrenal gland—breast cancer	8.7e-05	0.00183	CbGeAlD
Vandetanib—ABL1—pituitary gland—breast cancer	8.68e-05	0.00182	CbGeAlD
Vandetanib—ABL1—adipose tissue—breast cancer	8.65e-05	0.00181	CbGeAlD
Vandetanib—PDGFRB—bone marrow—breast cancer	8.42e-05	0.00177	CbGeAlD
Vandetanib—ORM1—female reproductive system—breast cancer	8.36e-05	0.00175	CbGeAlD
Vandetanib—MKNK1—lymph node—breast cancer	8.2e-05	0.00172	CbGeAlD
Vandetanib—PLK4—Doxorubicin—Idarubicin—breast cancer	8.16e-05	0.0492	CbGdCrCtD
Vandetanib—PLK4—Epirubicin—Idarubicin—breast cancer	8.16e-05	0.0492	CbGdCrCtD
Vandetanib—PDGFRB—female gonad—breast cancer	8.11e-05	0.0017	CbGeAlD
Vandetanib—FGR—lymph node—breast cancer	8.1e-05	0.0017	CbGeAlD
Vandetanib—LCK—lymph node—breast cancer	8.1e-05	0.0017	CbGeAlD
Vandetanib—RET—lymph node—breast cancer	8.1e-05	0.0017	CbGeAlD
Vandetanib—ERBB3—Vinblastine—Vinorelbine—breast cancer	8.07e-05	0.0486	CbGdCrCtD
Vandetanib—AXL—lymph node—breast cancer	8.06e-05	0.00169	CbGeAlD
Vandetanib—ABL1—female reproductive system—breast cancer	7.95e-05	0.00167	CbGeAlD
Vandetanib—ORM1—bone marrow—breast cancer	7.9e-05	0.00166	CbGeAlD
Vandetanib—Erlotinib—CYP1B1—breast cancer	7.89e-05	0.0246	CrCbGaD
Vandetanib—FMO3—lymph node—breast cancer	7.82e-05	0.00164	CbGeAlD
Vandetanib—SLK—lymph node—breast cancer	7.76e-05	0.00163	CbGeAlD
Vandetanib—ABL1—adrenal gland—breast cancer	7.76e-05	0.00163	CbGeAlD
Vandetanib—Afatinib—ABCG2—breast cancer	7.7e-05	0.0241	CrCbGaD
Vandetanib—Bosutinib—ABL1—breast cancer	7.55e-05	0.0236	CrCbGaD
Vandetanib—PDGFRB—endocrine gland—breast cancer	7.55e-05	0.00158	CbGeAlD
Vandetanib—FYN—lymph node—breast cancer	7.55e-05	0.00158	CbGeAlD
Vandetanib—ABL1—bone marrow—breast cancer	7.5e-05	0.00157	CbGeAlD
Vandetanib—Erlotinib—EGFR—breast cancer	7.45e-05	0.0233	CrCbGaD
Vandetanib—MAP4K5—lymph node—breast cancer	7.37e-05	0.00155	CbGeAlD
Vandetanib—TEK—lymph node—breast cancer	7.37e-05	0.00155	CbGeAlD
Vandetanib—ABCC1—endometrium—breast cancer	7.31e-05	0.00153	CbGeAlD
Vandetanib—ABL1—female gonad—breast cancer	7.23e-05	0.00152	CbGeAlD
Vandetanib—ALB—adrenal gland—breast cancer	7.16e-05	0.0015	CbGeAlD
Vandetanib—ORM1—endocrine gland—breast cancer	7.08e-05	0.00148	CbGeAlD
Vandetanib—EPHB6—lymph node—breast cancer	7.05e-05	0.00148	CbGeAlD
Vandetanib—ABL1—Doxorubicin—Idarubicin—breast cancer	6.86e-05	0.0414	CbGdCrCtD
Vandetanib—ABL1—Epirubicin—Idarubicin—breast cancer	6.86e-05	0.0414	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Idarubicin—breast cancer	6.86e-05	0.0414	CbGdCrCtD
Vandetanib—Bosutinib—SRC—breast cancer	6.83e-05	0.0213	CrCbGaD
Vandetanib—YES1—lymph node—breast cancer	6.81e-05	0.00143	CbGeAlD
Vandetanib—STK10—lymph node—breast cancer	6.75e-05	0.00142	CbGeAlD
Vandetanib—ABCC1—uterus—breast cancer	6.73e-05	0.00141	CbGeAlD
Vandetanib—ABL1—endocrine gland—breast cancer	6.73e-05	0.00141	CbGeAlD
Vandetanib—ABCC1—pituitary gland—breast cancer	6.61e-05	0.00139	CbGeAlD
Vandetanib—ABCC1—adipose tissue—breast cancer	6.59e-05	0.00138	CbGeAlD
Vandetanib—SRC—lymph node—breast cancer	6.55e-05	0.00137	CbGeAlD
Vandetanib—ABCG2—endometrium—breast cancer	6.05e-05	0.00127	CbGeAlD
Vandetanib—MAP2K5—lymph node—breast cancer	6.03e-05	0.00126	CbGeAlD
Vandetanib—KDR—lymph node—breast cancer	6.03e-05	0.00126	CbGeAlD
Vandetanib—ABCC1—adrenal gland—breast cancer	5.91e-05	0.00124	CbGeAlD
Vandetanib—ABCG2—uterus—breast cancer	5.58e-05	0.00117	CbGeAlD
Vandetanib—ABCC1—female gonad—breast cancer	5.51e-05	0.00116	CbGeAlD
Vandetanib—ABCG2—pituitary gland—breast cancer	5.48e-05	0.00115	CbGeAlD
Vandetanib—ABCG2—adipose tissue—breast cancer	5.45e-05	0.00114	CbGeAlD
Vandetanib—Erlotinib—ABCG2—breast cancer	5.44e-05	0.017	CrCbGaD
Vandetanib—PDGFRB—lymph node—breast cancer	5.22e-05	0.00109	CbGeAlD
Vandetanib—ORM1—lymph node—breast cancer	4.89e-05	0.00103	CbGeAlD
Vandetanib—ABCG2—adrenal gland—breast cancer	4.89e-05	0.00103	CbGeAlD
Vandetanib—ABCG2—bone marrow—breast cancer	4.73e-05	0.000992	CbGeAlD
Vandetanib—Gefitinib—EGFR—breast cancer	4.66e-05	0.0146	CrCbGaD
Vandetanib—ABL1—lymph node—breast cancer	4.65e-05	0.000975	CbGeAlD
Vandetanib—Bosutinib—EGFR—breast cancer	4.59e-05	0.0143	CrCbGaD
Vandetanib—ABCG2—female gonad—breast cancer	4.56e-05	0.000956	CbGeAlD
Vandetanib—ALB—lymph node—breast cancer	4.29e-05	0.0009	CbGeAlD
Vandetanib—Erlotinib—CYP1A1—breast cancer	4.26e-05	0.0133	CrCbGaD
Vandetanib—PLK4—Idarubicin—Epirubicin—breast cancer	3.75e-05	0.0226	CbGdCrCtD
Vandetanib—PLK4—Doxorubicin—Epirubicin—breast cancer	3.75e-05	0.0226	CbGdCrCtD
Vandetanib—ABCC1—lymph node—breast cancer	3.54e-05	0.000743	CbGeAlD
Vandetanib—CYP3A4—female reproductive system—breast cancer	3.49e-05	0.000732	CbGeAlD
Vandetanib—PLK4—Epirubicin—Doxorubicin—breast cancer	3.47e-05	0.0209	CbGdCrCtD
Vandetanib—PLK4—Idarubicin—Doxorubicin—breast cancer	3.47e-05	0.0209	CbGdCrCtD
Vandetanib—Gefitinib—ABCG2—breast cancer	3.41e-05	0.0106	CrCbGaD
Vandetanib—Afatinib—ABCB1—breast cancer	3.21e-05	0.01	CrCbGaD
Vandetanib—Erlotinib—CYP2D6—breast cancer	3.17e-05	0.0099	CrCbGaD
Vandetanib—ABL1—Idarubicin—Epirubicin—breast cancer	3.15e-05	0.019	CbGdCrCtD
Vandetanib—ABL1—Doxorubicin—Epirubicin—breast cancer	3.15e-05	0.019	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Epirubicin—breast cancer	3.15e-05	0.019	CbGdCrCtD
Vandetanib—CYP3A4—endocrine gland—breast cancer	2.95e-05	0.00062	CbGeAlD
Vandetanib—ABCG2—lymph node—breast cancer	2.93e-05	0.000615	CbGeAlD
Vandetanib—ABL1—Epirubicin—Doxorubicin—breast cancer	2.92e-05	0.0176	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Doxorubicin—breast cancer	2.92e-05	0.0176	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Doxorubicin—breast cancer	2.92e-05	0.0176	CbGdCrCtD
Vandetanib—VEGFA—Dexamethasone—Fluoxymesterone—breast cancer	2.78e-05	0.0168	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Fluoxymesterone—breast cancer	2.78e-05	0.0168	CbGdCrCtD
Vandetanib—Erlotinib—CYP3A4—breast cancer	2.72e-05	0.00849	CrCbGaD
Vandetanib—Gefitinib—CYP1A1—breast cancer	2.67e-05	0.00833	CrCbGaD
Vandetanib—Erlotinib—ALB—breast cancer	2.37e-05	0.00741	CrCbGaD
Vandetanib—Erlotinib—ABCB1—breast cancer	2.27e-05	0.00707	CrCbGaD
Vandetanib—Gefitinib—CYP2D6—breast cancer	1.99e-05	0.0062	CrCbGaD
Vandetanib—Gefitinib—CYP3A4—breast cancer	1.7e-05	0.00532	CrCbGaD
Vandetanib—Bosutinib—CYP3A4—breast cancer	1.68e-05	0.00523	CrCbGaD
Vandetanib—Pneumonia—Doxorubicin—breast cancer	1.5e-05	0.000179	CcSEcCtD
Vandetanib—Nervous system disorder—Docetaxel—breast cancer	1.49e-05	0.000178	CcSEcCtD
Vandetanib—Pruritus—Fluorouracil—breast cancer	1.49e-05	0.000178	CcSEcCtD
Vandetanib—Thrombocytopenia—Docetaxel—breast cancer	1.49e-05	0.000178	CcSEcCtD
Vandetanib—Infestation NOS—Doxorubicin—breast cancer	1.49e-05	0.000178	CcSEcCtD
Vandetanib—Infestation—Doxorubicin—breast cancer	1.49e-05	0.000178	CcSEcCtD
Vandetanib—Visual impairment—Methotrexate—breast cancer	1.49e-05	0.000178	CcSEcCtD
Vandetanib—Gefitinib—ALB—breast cancer	1.49e-05	0.00464	CrCbGaD
Vandetanib—Skin disorder—Docetaxel—breast cancer	1.48e-05	0.000176	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Doxorubicin—breast cancer	1.48e-05	0.000176	CcSEcCtD
Vandetanib—Oedema—Capecitabine—breast cancer	1.48e-05	0.000176	CcSEcCtD
Vandetanib—Bradycardia—Epirubicin—breast cancer	1.47e-05	0.000176	CcSEcCtD
Vandetanib—Gastrointestinal pain—Paclitaxel—breast cancer	1.47e-05	0.000175	CcSEcCtD
Vandetanib—Diarrhoea—Gemcitabine—breast cancer	1.47e-05	0.000175	CcSEcCtD
Vandetanib—Renal failure—Doxorubicin—breast cancer	1.47e-05	0.000175	CcSEcCtD
Vandetanib—Infection—Capecitabine—breast cancer	1.47e-05	0.000175	CcSEcCtD
Vandetanib—Erythema multiforme—Methotrexate—breast cancer	1.46e-05	0.000174	CcSEcCtD
Vandetanib—Dizziness—Irinotecan—breast cancer	1.46e-05	0.000174	CcSEcCtD
Vandetanib—Haemoglobin—Epirubicin—breast cancer	1.45e-05	0.000173	CcSEcCtD
Vandetanib—Stomatitis—Doxorubicin—breast cancer	1.45e-05	0.000173	CcSEcCtD
Vandetanib—Urinary tract infection—Doxorubicin—breast cancer	1.45e-05	0.000173	CcSEcCtD
Vandetanib—Conjunctivitis—Doxorubicin—breast cancer	1.45e-05	0.000173	CcSEcCtD
Vandetanib—Nervous system disorder—Capecitabine—breast cancer	1.45e-05	0.000173	CcSEcCtD
Vandetanib—Haemorrhage—Epirubicin—breast cancer	1.45e-05	0.000172	CcSEcCtD
Vandetanib—Eye disorder—Methotrexate—breast cancer	1.44e-05	0.000172	CcSEcCtD
Vandetanib—Diarrhoea—Fluorouracil—breast cancer	1.44e-05	0.000172	CcSEcCtD
Vandetanib—Thrombocytopenia—Capecitabine—breast cancer	1.44e-05	0.000172	CcSEcCtD
Vandetanib—Cardiac disorder—Methotrexate—breast cancer	1.43e-05	0.000171	CcSEcCtD
Vandetanib—Skin disorder—Capecitabine—breast cancer	1.43e-05	0.000171	CcSEcCtD
Vandetanib—Urinary tract disorder—Epirubicin—breast cancer	1.43e-05	0.00017	CcSEcCtD
Vandetanib—Haematuria—Doxorubicin—breast cancer	1.42e-05	0.00017	CcSEcCtD
Vandetanib—Abdominal pain—Paclitaxel—breast cancer	1.42e-05	0.000169	CcSEcCtD
Vandetanib—Body temperature increased—Paclitaxel—breast cancer	1.42e-05	0.000169	CcSEcCtD
Vandetanib—Urethral disorder—Epirubicin—breast cancer	1.42e-05	0.000169	CcSEcCtD
Vandetanib—Gefitinib—ABCB1—breast cancer	1.42e-05	0.00443	CrCbGaD
Vandetanib—Hepatobiliary disease—Doxorubicin—breast cancer	1.41e-05	0.000168	CcSEcCtD
Vandetanib—Epistaxis—Doxorubicin—breast cancer	1.41e-05	0.000168	CcSEcCtD
Vandetanib—Angiopathy—Methotrexate—breast cancer	1.4e-05	0.000167	CcSEcCtD
Vandetanib—Vomiting—Mitoxantrone—breast cancer	1.4e-05	0.000167	CcSEcCtD
Vandetanib—Vomiting—Irinotecan—breast cancer	1.4e-05	0.000167	CcSEcCtD
Vandetanib—Sinusitis—Doxorubicin—breast cancer	1.4e-05	0.000167	CcSEcCtD
Vandetanib—Dizziness—Fluorouracil—breast cancer	1.4e-05	0.000166	CcSEcCtD
Vandetanib—Bosutinib—ABCB1—breast cancer	1.4e-05	0.00436	CrCbGaD
Vandetanib—Visual impairment—Epirubicin—breast cancer	1.39e-05	0.000166	CcSEcCtD
Vandetanib—Mediastinal disorder—Methotrexate—breast cancer	1.39e-05	0.000166	CcSEcCtD
Vandetanib—Rash—Mitoxantrone—breast cancer	1.39e-05	0.000166	CcSEcCtD
Vandetanib—Rash—Irinotecan—breast cancer	1.39e-05	0.000166	CcSEcCtD
Vandetanib—Dermatitis—Mitoxantrone—breast cancer	1.39e-05	0.000166	CcSEcCtD
Vandetanib—Dermatitis—Irinotecan—breast cancer	1.39e-05	0.000166	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Docetaxel—breast cancer	1.39e-05	0.000166	CcSEcCtD
Vandetanib—Headache—Mitoxantrone—breast cancer	1.38e-05	0.000165	CcSEcCtD
Vandetanib—Headache—Irinotecan—breast cancer	1.38e-05	0.000165	CcSEcCtD
Vandetanib—Insomnia—Docetaxel—breast cancer	1.38e-05	0.000164	CcSEcCtD
Vandetanib—Paraesthesia—Docetaxel—breast cancer	1.37e-05	0.000163	CcSEcCtD
Vandetanib—Erythema multiforme—Epirubicin—breast cancer	1.37e-05	0.000163	CcSEcCtD
Vandetanib—Alopecia—Methotrexate—breast cancer	1.37e-05	0.000163	CcSEcCtD
Vandetanib—Vomiting—Gemcitabine—breast cancer	1.37e-05	0.000163	CcSEcCtD
Vandetanib—Bradycardia—Doxorubicin—breast cancer	1.36e-05	0.000162	CcSEcCtD
Vandetanib—Dyspnoea—Docetaxel—breast cancer	1.36e-05	0.000162	CcSEcCtD
Vandetanib—Mental disorder—Methotrexate—breast cancer	1.35e-05	0.000161	CcSEcCtD
Vandetanib—Rash—Gemcitabine—breast cancer	1.35e-05	0.000161	CcSEcCtD
Vandetanib—Dermatitis—Gemcitabine—breast cancer	1.35e-05	0.000161	CcSEcCtD
Vandetanib—Eye disorder—Epirubicin—breast cancer	1.35e-05	0.000161	CcSEcCtD
Vandetanib—Malnutrition—Methotrexate—breast cancer	1.35e-05	0.00016	CcSEcCtD
Vandetanib—Haemoglobin—Doxorubicin—breast cancer	1.35e-05	0.00016	CcSEcCtD
Vandetanib—Headache—Gemcitabine—breast cancer	1.35e-05	0.00016	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Capecitabine—breast cancer	1.34e-05	0.00016	CcSEcCtD
Vandetanib—Cardiac disorder—Epirubicin—breast cancer	1.34e-05	0.00016	CcSEcCtD
Vandetanib—Vomiting—Fluorouracil—breast cancer	1.34e-05	0.00016	CcSEcCtD
Vandetanib—Dyspepsia—Docetaxel—breast cancer	1.34e-05	0.00016	CcSEcCtD
Vandetanib—Haemorrhage—Doxorubicin—breast cancer	1.34e-05	0.00016	CcSEcCtD
Vandetanib—Insomnia—Capecitabine—breast cancer	1.33e-05	0.000159	CcSEcCtD
Vandetanib—Rash—Fluorouracil—breast cancer	1.33e-05	0.000159	CcSEcCtD
Vandetanib—Dermatitis—Fluorouracil—breast cancer	1.33e-05	0.000159	CcSEcCtD
Vandetanib—Paraesthesia—Capecitabine—breast cancer	1.32e-05	0.000158	CcSEcCtD
Vandetanib—Decreased appetite—Docetaxel—breast cancer	1.32e-05	0.000158	CcSEcCtD
Vandetanib—Headache—Fluorouracil—breast cancer	1.32e-05	0.000158	CcSEcCtD
Vandetanib—Urinary tract disorder—Doxorubicin—breast cancer	1.32e-05	0.000158	CcSEcCtD
Vandetanib—Dysgeusia—Methotrexate—breast cancer	1.32e-05	0.000157	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Docetaxel—breast cancer	1.32e-05	0.000157	CcSEcCtD
Vandetanib—Dyspnoea—Capecitabine—breast cancer	1.32e-05	0.000157	CcSEcCtD
Vandetanib—Fatigue—Docetaxel—breast cancer	1.31e-05	0.000157	CcSEcCtD
Vandetanib—Angiopathy—Epirubicin—breast cancer	1.31e-05	0.000157	CcSEcCtD
Vandetanib—Urethral disorder—Doxorubicin—breast cancer	1.31e-05	0.000156	CcSEcCtD
Vandetanib—Nausea—Mitoxantrone—breast cancer	1.31e-05	0.000156	CcSEcCtD
Vandetanib—Nausea—Irinotecan—breast cancer	1.31e-05	0.000156	CcSEcCtD
Vandetanib—Mediastinal disorder—Epirubicin—breast cancer	1.3e-05	0.000155	CcSEcCtD
Vandetanib—Pain—Docetaxel—breast cancer	1.3e-05	0.000155	CcSEcCtD
Vandetanib—Constipation—Docetaxel—breast cancer	1.3e-05	0.000155	CcSEcCtD
Vandetanib—Dyspepsia—Capecitabine—breast cancer	1.3e-05	0.000155	CcSEcCtD
Vandetanib—Arrhythmia—Epirubicin—breast cancer	1.29e-05	0.000154	CcSEcCtD
Vandetanib—Visual impairment—Doxorubicin—breast cancer	1.29e-05	0.000154	CcSEcCtD
Vandetanib—Asthenia—Paclitaxel—breast cancer	1.29e-05	0.000154	CcSEcCtD
Vandetanib—Decreased appetite—Capecitabine—breast cancer	1.28e-05	0.000153	CcSEcCtD
Vandetanib—Alopecia—Epirubicin—breast cancer	1.28e-05	0.000152	CcSEcCtD
Vandetanib—Nausea—Gemcitabine—breast cancer	1.28e-05	0.000152	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Capecitabine—breast cancer	1.27e-05	0.000152	CcSEcCtD
Vandetanib—Fatigue—Capecitabine—breast cancer	1.27e-05	0.000152	CcSEcCtD
Vandetanib—Pruritus—Paclitaxel—breast cancer	1.27e-05	0.000152	CcSEcCtD
Vandetanib—Vision blurred—Methotrexate—breast cancer	1.27e-05	0.000151	CcSEcCtD
Vandetanib—Mental disorder—Epirubicin—breast cancer	1.27e-05	0.000151	CcSEcCtD
Vandetanib—Erythema multiforme—Doxorubicin—breast cancer	1.27e-05	0.000151	CcSEcCtD
Vandetanib—Pain—Capecitabine—breast cancer	1.26e-05	0.00015	CcSEcCtD
Vandetanib—Constipation—Capecitabine—breast cancer	1.26e-05	0.00015	CcSEcCtD
Vandetanib—Malnutrition—Epirubicin—breast cancer	1.26e-05	0.00015	CcSEcCtD
Vandetanib—Nausea—Fluorouracil—breast cancer	1.25e-05	0.00015	CcSEcCtD
Vandetanib—Eye disorder—Doxorubicin—breast cancer	1.25e-05	0.000149	CcSEcCtD
Vandetanib—Gastrointestinal pain—Docetaxel—breast cancer	1.25e-05	0.000149	CcSEcCtD
Vandetanib—Cardiac disorder—Doxorubicin—breast cancer	1.24e-05	0.000148	CcSEcCtD
Vandetanib—Dysgeusia—Epirubicin—breast cancer	1.23e-05	0.000147	CcSEcCtD
Vandetanib—Diarrhoea—Paclitaxel—breast cancer	1.23e-05	0.000147	CcSEcCtD
Vandetanib—Angiopathy—Doxorubicin—breast cancer	1.21e-05	0.000145	CcSEcCtD
Vandetanib—Muscle spasms—Epirubicin—breast cancer	1.21e-05	0.000144	CcSEcCtD
Vandetanib—Gastrointestinal pain—Capecitabine—breast cancer	1.21e-05	0.000144	CcSEcCtD
Vandetanib—Mediastinal disorder—Doxorubicin—breast cancer	1.21e-05	0.000144	CcSEcCtD
Vandetanib—Body temperature increased—Docetaxel—breast cancer	1.2e-05	0.000144	CcSEcCtD
Vandetanib—Abdominal pain—Docetaxel—breast cancer	1.2e-05	0.000144	CcSEcCtD
Vandetanib—Arrhythmia—Doxorubicin—breast cancer	1.2e-05	0.000143	CcSEcCtD
Vandetanib—Dizziness—Paclitaxel—breast cancer	1.19e-05	0.000142	CcSEcCtD
Vandetanib—Vision blurred—Epirubicin—breast cancer	1.19e-05	0.000142	CcSEcCtD
Vandetanib—Alopecia—Doxorubicin—breast cancer	1.18e-05	0.000141	CcSEcCtD
Vandetanib—Cough—Methotrexate—breast cancer	1.17e-05	0.00014	CcSEcCtD
Vandetanib—Mental disorder—Doxorubicin—breast cancer	1.17e-05	0.00014	CcSEcCtD
Vandetanib—Abdominal pain—Capecitabine—breast cancer	1.17e-05	0.000139	CcSEcCtD
Vandetanib—Body temperature increased—Capecitabine—breast cancer	1.17e-05	0.000139	CcSEcCtD
Vandetanib—Convulsion—Methotrexate—breast cancer	1.17e-05	0.000139	CcSEcCtD
Vandetanib—Malnutrition—Doxorubicin—breast cancer	1.17e-05	0.000139	CcSEcCtD
Vandetanib—Chest pain—Methotrexate—breast cancer	1.15e-05	0.000137	CcSEcCtD
Vandetanib—Arthralgia—Methotrexate—breast cancer	1.15e-05	0.000137	CcSEcCtD
Vandetanib—Vomiting—Paclitaxel—breast cancer	1.14e-05	0.000136	CcSEcCtD
Vandetanib—Dysgeusia—Doxorubicin—breast cancer	1.14e-05	0.000136	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.14e-05	0.000136	CcSEcCtD
Vandetanib—Rash—Paclitaxel—breast cancer	1.13e-05	0.000135	CcSEcCtD
Vandetanib—Dermatitis—Paclitaxel—breast cancer	1.13e-05	0.000135	CcSEcCtD
Vandetanib—Headache—Paclitaxel—breast cancer	1.13e-05	0.000134	CcSEcCtD
Vandetanib—Muscle spasms—Doxorubicin—breast cancer	1.12e-05	0.000134	CcSEcCtD
Vandetanib—Loss of consciousness—Epirubicin—breast cancer	1.11e-05	0.000132	CcSEcCtD
Vandetanib—Cough—Epirubicin—breast cancer	1.1e-05	0.000131	CcSEcCtD
Vandetanib—Vision blurred—Doxorubicin—breast cancer	1.1e-05	0.000131	CcSEcCtD
Vandetanib—Asthenia—Docetaxel—breast cancer	1.09e-05	0.00013	CcSEcCtD
Vandetanib—Convulsion—Epirubicin—breast cancer	1.09e-05	0.00013	CcSEcCtD
Vandetanib—Infection—Methotrexate—breast cancer	1.09e-05	0.00013	CcSEcCtD
Vandetanib—Hypertension—Epirubicin—breast cancer	1.09e-05	0.00013	CcSEcCtD
Vandetanib—Pruritus—Docetaxel—breast cancer	1.08e-05	0.000129	CcSEcCtD
Vandetanib—Nervous system disorder—Methotrexate—breast cancer	1.08e-05	0.000128	CcSEcCtD
Vandetanib—Thrombocytopenia—Methotrexate—breast cancer	1.08e-05	0.000128	CcSEcCtD
Vandetanib—Chest pain—Epirubicin—breast cancer	1.07e-05	0.000128	CcSEcCtD
Vandetanib—Arthralgia—Epirubicin—breast cancer	1.07e-05	0.000128	CcSEcCtD
Vandetanib—Anxiety—Epirubicin—breast cancer	1.07e-05	0.000127	CcSEcCtD
Vandetanib—Nausea—Paclitaxel—breast cancer	1.07e-05	0.000127	CcSEcCtD
Vandetanib—Skin disorder—Methotrexate—breast cancer	1.07e-05	0.000127	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.06e-05	0.000127	CcSEcCtD
Vandetanib—Asthenia—Capecitabine—breast cancer	1.06e-05	0.000126	CcSEcCtD
Vandetanib—Dry mouth—Epirubicin—breast cancer	1.05e-05	0.000125	CcSEcCtD
Vandetanib—Pruritus—Capecitabine—breast cancer	1.04e-05	0.000124	CcSEcCtD
Vandetanib—Diarrhoea—Docetaxel—breast cancer	1.04e-05	0.000124	CcSEcCtD
Vandetanib—Oedema—Epirubicin—breast cancer	1.03e-05	0.000123	CcSEcCtD
Vandetanib—Loss of consciousness—Doxorubicin—breast cancer	1.02e-05	0.000122	CcSEcCtD
Vandetanib—Infection—Epirubicin—breast cancer	1.02e-05	0.000122	CcSEcCtD
Vandetanib—Cough—Doxorubicin—breast cancer	1.02e-05	0.000121	CcSEcCtD
Vandetanib—Convulsion—Doxorubicin—breast cancer	1.01e-05	0.00012	CcSEcCtD
Vandetanib—Diarrhoea—Capecitabine—breast cancer	1.01e-05	0.00012	CcSEcCtD
Vandetanib—Nervous system disorder—Epirubicin—breast cancer	1.01e-05	0.00012	CcSEcCtD
Vandetanib—Dizziness—Docetaxel—breast cancer	1.01e-05	0.00012	CcSEcCtD
Vandetanib—Thrombocytopenia—Epirubicin—breast cancer	1.01e-05	0.00012	CcSEcCtD
Vandetanib—Hypertension—Doxorubicin—breast cancer	1.01e-05	0.00012	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Methotrexate—breast cancer	1e-05	0.000119	CcSEcCtD
Vandetanib—Skin disorder—Epirubicin—breast cancer	9.98e-06	0.000119	CcSEcCtD
Vandetanib—Insomnia—Methotrexate—breast cancer	9.93e-06	0.000118	CcSEcCtD
Vandetanib—Chest pain—Doxorubicin—breast cancer	9.92e-06	0.000118	CcSEcCtD
Vandetanib—Arthralgia—Doxorubicin—breast cancer	9.92e-06	0.000118	CcSEcCtD
Vandetanib—Anxiety—Doxorubicin—breast cancer	9.89e-06	0.000118	CcSEcCtD
Vandetanib—Paraesthesia—Methotrexate—breast cancer	9.86e-06	0.000118	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	9.85e-06	0.000117	CcSEcCtD
Vandetanib—Dyspnoea—Methotrexate—breast cancer	9.79e-06	0.000117	CcSEcCtD
Vandetanib—Dizziness—Capecitabine—breast cancer	9.76e-06	0.000116	CcSEcCtD
Vandetanib—Dry mouth—Doxorubicin—breast cancer	9.7e-06	0.000116	CcSEcCtD
Vandetanib—Vomiting—Docetaxel—breast cancer	9.69e-06	0.000116	CcSEcCtD
Vandetanib—Dyspepsia—Methotrexate—breast cancer	9.67e-06	0.000115	CcSEcCtD
Vandetanib—Rash—Docetaxel—breast cancer	9.61e-06	0.000115	CcSEcCtD
Vandetanib—Dermatitis—Docetaxel—breast cancer	9.6e-06	0.000114	CcSEcCtD
Vandetanib—Decreased appetite—Methotrexate—breast cancer	9.55e-06	0.000114	CcSEcCtD
Vandetanib—Headache—Docetaxel—breast cancer	9.55e-06	0.000114	CcSEcCtD
Vandetanib—Oedema—Doxorubicin—breast cancer	9.51e-06	0.000113	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Methotrexate—breast cancer	9.48e-06	0.000113	CcSEcCtD
Vandetanib—Fatigue—Methotrexate—breast cancer	9.47e-06	0.000113	CcSEcCtD
Vandetanib—Infection—Doxorubicin—breast cancer	9.45e-06	0.000113	CcSEcCtD
Vandetanib—Pain—Methotrexate—breast cancer	9.39e-06	0.000112	CcSEcCtD
Vandetanib—Vomiting—Capecitabine—breast cancer	9.38e-06	0.000112	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Epirubicin—breast cancer	9.37e-06	0.000112	CcSEcCtD
Vandetanib—Nervous system disorder—Doxorubicin—breast cancer	9.33e-06	0.000111	CcSEcCtD
Vandetanib—Thrombocytopenia—Doxorubicin—breast cancer	9.31e-06	0.000111	CcSEcCtD
Vandetanib—Rash—Capecitabine—breast cancer	9.3e-06	0.000111	CcSEcCtD
Vandetanib—Insomnia—Epirubicin—breast cancer	9.3e-06	0.000111	CcSEcCtD
Vandetanib—Dermatitis—Capecitabine—breast cancer	9.29e-06	0.000111	CcSEcCtD
Vandetanib—Headache—Capecitabine—breast cancer	9.24e-06	0.00011	CcSEcCtD
Vandetanib—Skin disorder—Doxorubicin—breast cancer	9.24e-06	0.00011	CcSEcCtD
Vandetanib—Paraesthesia—Epirubicin—breast cancer	9.23e-06	0.00011	CcSEcCtD
Vandetanib—Dyspnoea—Epirubicin—breast cancer	9.16e-06	0.000109	CcSEcCtD
Vandetanib—Nausea—Docetaxel—breast cancer	9.05e-06	0.000108	CcSEcCtD
Vandetanib—Dyspepsia—Epirubicin—breast cancer	9.05e-06	0.000108	CcSEcCtD
Vandetanib—Gastrointestinal pain—Methotrexate—breast cancer	8.98e-06	0.000107	CcSEcCtD
Vandetanib—Decreased appetite—Epirubicin—breast cancer	8.94e-06	0.000107	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Epirubicin—breast cancer	8.87e-06	0.000106	CcSEcCtD
Vandetanib—Fatigue—Epirubicin—breast cancer	8.86e-06	0.000106	CcSEcCtD
Vandetanib—Constipation—Epirubicin—breast cancer	8.79e-06	0.000105	CcSEcCtD
Vandetanib—Pain—Epirubicin—breast cancer	8.79e-06	0.000105	CcSEcCtD
Vandetanib—Nausea—Capecitabine—breast cancer	8.76e-06	0.000104	CcSEcCtD
Vandetanib—Abdominal pain—Methotrexate—breast cancer	8.68e-06	0.000104	CcSEcCtD
Vandetanib—Body temperature increased—Methotrexate—breast cancer	8.68e-06	0.000104	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Doxorubicin—breast cancer	8.67e-06	0.000103	CcSEcCtD
Vandetanib—Insomnia—Doxorubicin—breast cancer	8.6e-06	0.000103	CcSEcCtD
Vandetanib—Paraesthesia—Doxorubicin—breast cancer	8.54e-06	0.000102	CcSEcCtD
Vandetanib—Dyspnoea—Doxorubicin—breast cancer	8.48e-06	0.000101	CcSEcCtD
Vandetanib—Gastrointestinal pain—Epirubicin—breast cancer	8.41e-06	0.0001	CcSEcCtD
Vandetanib—Dyspepsia—Doxorubicin—breast cancer	8.37e-06	9.98e-05	CcSEcCtD
Vandetanib—Decreased appetite—Doxorubicin—breast cancer	8.27e-06	9.86e-05	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Doxorubicin—breast cancer	8.21e-06	9.79e-05	CcSEcCtD
Vandetanib—Fatigue—Doxorubicin—breast cancer	8.2e-06	9.78e-05	CcSEcCtD
Vandetanib—Pain—Doxorubicin—breast cancer	8.13e-06	9.7e-05	CcSEcCtD
Vandetanib—Constipation—Doxorubicin—breast cancer	8.13e-06	9.7e-05	CcSEcCtD
Vandetanib—Abdominal pain—Epirubicin—breast cancer	8.13e-06	9.69e-05	CcSEcCtD
Vandetanib—Body temperature increased—Epirubicin—breast cancer	8.13e-06	9.69e-05	CcSEcCtD
Vandetanib—Asthenia—Methotrexate—breast cancer	7.88e-06	9.4e-05	CcSEcCtD
Vandetanib—Gastrointestinal pain—Doxorubicin—breast cancer	7.78e-06	9.27e-05	CcSEcCtD
Vandetanib—Pruritus—Methotrexate—breast cancer	7.77e-06	9.26e-05	CcSEcCtD
Vandetanib—Abdominal pain—Doxorubicin—breast cancer	7.52e-06	8.96e-05	CcSEcCtD
Vandetanib—Body temperature increased—Doxorubicin—breast cancer	7.52e-06	8.96e-05	CcSEcCtD
Vandetanib—Diarrhoea—Methotrexate—breast cancer	7.52e-06	8.96e-05	CcSEcCtD
Vandetanib—Asthenia—Epirubicin—breast cancer	7.37e-06	8.79e-05	CcSEcCtD
Vandetanib—Pruritus—Epirubicin—breast cancer	7.27e-06	8.67e-05	CcSEcCtD
Vandetanib—Dizziness—Methotrexate—breast cancer	7.26e-06	8.66e-05	CcSEcCtD
Vandetanib—Diarrhoea—Epirubicin—breast cancer	7.03e-06	8.39e-05	CcSEcCtD
Vandetanib—Vomiting—Methotrexate—breast cancer	6.98e-06	8.33e-05	CcSEcCtD
Vandetanib—Rash—Methotrexate—breast cancer	6.93e-06	8.26e-05	CcSEcCtD
Vandetanib—Dermatitis—Methotrexate—breast cancer	6.92e-06	8.25e-05	CcSEcCtD
Vandetanib—Headache—Methotrexate—breast cancer	6.88e-06	8.2e-05	CcSEcCtD
Vandetanib—Asthenia—Doxorubicin—breast cancer	6.82e-06	8.14e-05	CcSEcCtD
Vandetanib—Dizziness—Epirubicin—breast cancer	6.8e-06	8.1e-05	CcSEcCtD
Vandetanib—Pruritus—Doxorubicin—breast cancer	6.73e-06	8.02e-05	CcSEcCtD
Vandetanib—Vomiting—Epirubicin—breast cancer	6.54e-06	7.79e-05	CcSEcCtD
Vandetanib—Nausea—Methotrexate—breast cancer	6.52e-06	7.78e-05	CcSEcCtD
Vandetanib—Diarrhoea—Doxorubicin—breast cancer	6.51e-06	7.76e-05	CcSEcCtD
Vandetanib—Rash—Epirubicin—breast cancer	6.48e-06	7.73e-05	CcSEcCtD
Vandetanib—Dermatitis—Epirubicin—breast cancer	6.48e-06	7.72e-05	CcSEcCtD
Vandetanib—Headache—Epirubicin—breast cancer	6.44e-06	7.68e-05	CcSEcCtD
Vandetanib—Dizziness—Doxorubicin—breast cancer	6.29e-06	7.5e-05	CcSEcCtD
Vandetanib—Nausea—Epirubicin—breast cancer	6.11e-06	7.28e-05	CcSEcCtD
Vandetanib—Vomiting—Doxorubicin—breast cancer	6.05e-06	7.21e-05	CcSEcCtD
Vandetanib—Rash—Doxorubicin—breast cancer	6e-06	7.15e-05	CcSEcCtD
Vandetanib—Dermatitis—Doxorubicin—breast cancer	5.99e-06	7.14e-05	CcSEcCtD
Vandetanib—Headache—Doxorubicin—breast cancer	5.96e-06	7.1e-05	CcSEcCtD
Vandetanib—Nausea—Doxorubicin—breast cancer	5.65e-06	6.74e-05	CcSEcCtD
Vandetanib—ALB—Metabolism—CAV1—breast cancer	2.21e-07	2.33e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—RAF1—breast cancer	2.21e-07	2.33e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—TGFB1—breast cancer	2.21e-07	2.32e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—RELA—breast cancer	2.2e-07	2.32e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL6—breast cancer	2.2e-07	2.31e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL6—breast cancer	2.2e-07	2.31e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CD—breast cancer	2.2e-07	2.31e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK8—breast cancer	2.19e-07	2.31e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL6—breast cancer	2.19e-07	2.3e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ERBB2—breast cancer	2.19e-07	2.3e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—MAPK3—breast cancer	2.19e-07	2.3e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP17A1—breast cancer	2.18e-07	2.29e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL6—breast cancer	2.17e-07	2.29e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SERPINE1—breast cancer	2.17e-07	2.28e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—HRAS—breast cancer	2.17e-07	2.28e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—EGFR—breast cancer	2.17e-07	2.28e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL6—breast cancer	2.17e-07	2.28e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTEN—breast cancer	2.16e-07	2.28e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MTOR—breast cancer	2.16e-07	2.27e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CB—breast cancer	2.16e-07	2.27e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—breast cancer	2.16e-07	2.27e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—SRC—breast cancer	2.16e-07	2.27e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ENO1—breast cancer	2.16e-07	2.27e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS1—breast cancer	2.16e-07	2.27e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—PIK3CA—breast cancer	2.16e-07	2.27e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CXCL8—breast cancer	2.16e-07	2.27e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—HRAS—breast cancer	2.15e-07	2.26e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HRAS—breast cancer	2.14e-07	2.25e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—KRAS—breast cancer	2.13e-07	2.23e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.12e-07	2.22e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP2D6—breast cancer	2.12e-07	2.22e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—PIK3CA—breast cancer	2.11e-07	2.22e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—SRC—breast cancer	2.11e-07	2.22e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—STAT3—breast cancer	2.11e-07	2.22e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CDKN1B—breast cancer	2.11e-07	2.21e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—breast cancer	2.1e-07	2.21e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—HRAS—breast cancer	2.09e-07	2.2e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—breast cancer	2.09e-07	2.19e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—breast cancer	2.08e-07	2.19e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—STAT3—breast cancer	2.08e-07	2.19e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—SRC—breast cancer	2.08e-07	2.19e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—EGFR—breast cancer	2.08e-07	2.19e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CXCL8—breast cancer	2.08e-07	2.18e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—IL6—breast cancer	2.08e-07	2.18e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NCOA2—breast cancer	2.08e-07	2.18e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—breast cancer	2.07e-07	2.18e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NOS3—breast cancer	2.07e-07	2.18e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PIK3CA—breast cancer	2.07e-07	2.18e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HRAS—breast cancer	2.07e-07	2.17e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CASP3—breast cancer	2.06e-07	2.17e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL2—breast cancer	2.06e-07	2.17e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—breast cancer	2.06e-07	2.16e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL6—breast cancer	2.05e-07	2.15e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—KRAS—breast cancer	2.05e-07	2.15e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—PIK3CA—breast cancer	2.04e-07	2.14e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—STAT3—breast cancer	2.04e-07	2.14e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—breast cancer	2.03e-07	2.14e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—breast cancer	2.03e-07	2.13e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CDKN1B—breast cancer	2.03e-07	2.13e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—breast cancer	2.03e-07	2.13e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—breast cancer	2.02e-07	2.13e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MAPK3—breast cancer	2.02e-07	2.12e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CG—breast cancer	2.02e-07	2.12e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—FASN—breast cancer	2.01e-07	2.12e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCND1—breast cancer	2.01e-07	2.11e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—STAT3—breast cancer	2.01e-07	2.11e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—breast cancer	2.01e-07	2.11e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—BCHE—breast cancer	2.01e-07	2.11e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—JUN—breast cancer	2e-07	2.11e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—IL6—breast cancer	2e-07	2.1e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—breast cancer	2e-07	2.1e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HRAS—breast cancer	1.99e-07	2.1e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK3—breast cancer	1.99e-07	2.09e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CTNNB1—breast cancer	1.99e-07	2.09e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CASP3—breast cancer	1.99e-07	2.09e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL2—breast cancer	1.99e-07	2.09e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC5A5—breast cancer	1.98e-07	2.08e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL6—breast cancer	1.98e-07	2.08e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MDM2—breast cancer	1.97e-07	2.07e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—KRAS—breast cancer	1.96e-07	2.06e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MYC—breast cancer	1.96e-07	2.06e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RAF1—breast cancer	1.96e-07	2.06e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—TGFB1—breast cancer	1.96e-07	2.06e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HRAS—breast cancer	1.96e-07	2.06e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—PIK3CA—breast cancer	1.95e-07	2.05e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RELA—breast cancer	1.95e-07	2.05e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP9—breast cancer	1.95e-07	2.05e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK3—breast cancer	1.95e-07	2.05e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CDKN1A—breast cancer	1.94e-07	2.04e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ERBB2—breast cancer	1.94e-07	2.04e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PTEN—breast cancer	1.94e-07	2.04e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCND1—breast cancer	1.94e-07	2.03e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MYC—breast cancer	1.93e-07	2.03e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—JUN—breast cancer	1.93e-07	2.03e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TGFB1—breast cancer	1.93e-07	2.03e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—EGFR—breast cancer	1.92e-07	2.02e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK3—breast cancer	1.92e-07	2.02e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HRAS—breast cancer	1.92e-07	2.02e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CTNNB1—breast cancer	1.92e-07	2.01e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—breast cancer	1.92e-07	2.01e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CB—breast cancer	1.91e-07	2.01e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MTOR—breast cancer	1.91e-07	2.01e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NQO1—breast cancer	1.91e-07	2.01e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC2A1—breast cancer	1.91e-07	2.01e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL6—breast cancer	1.91e-07	2.01e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—breast cancer	1.9e-07	2e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK8—breast cancer	1.9e-07	1.99e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MYC—breast cancer	1.89e-07	1.99e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EGFR—breast cancer	1.89e-07	1.99e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—breast cancer	1.89e-07	1.99e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TGFB1—breast cancer	1.89e-07	1.99e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—HRAS—breast cancer	1.89e-07	1.98e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—PIK3CA—breast cancer	1.88e-07	1.98e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP9—breast cancer	1.88e-07	1.98e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL6—breast cancer	1.87e-07	1.97e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CDKN1A—breast cancer	1.87e-07	1.97e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PTEN—breast cancer	1.87e-07	1.96e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MYC—breast cancer	1.86e-07	1.96e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TGFB1—breast cancer	1.86e-07	1.96e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EGFR—breast cancer	1.85e-07	1.95e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—breast cancer	1.85e-07	1.94e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CXCL8—breast cancer	1.84e-07	1.93e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IL6—breast cancer	1.83e-07	1.93e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP1B1—breast cancer	1.83e-07	1.93e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK8—breast cancer	1.83e-07	1.92e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EGFR—breast cancer	1.82e-07	1.92e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—breast cancer	1.82e-07	1.92e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—KRAS—breast cancer	1.81e-07	1.91e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—HRAS—breast cancer	1.81e-07	1.9e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL6—breast cancer	1.8e-07	1.9e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—PIK3CA—breast cancer	1.8e-07	1.9e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HSP90AA1—breast cancer	1.8e-07	1.89e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SRC—breast cancer	1.8e-07	1.89e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CDKN1B—breast cancer	1.8e-07	1.89e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KRAS—breast cancer	1.79e-07	1.88e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CD—breast cancer	1.77e-07	1.86e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—breast cancer	1.76e-07	1.85e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CASP3—breast cancer	1.76e-07	1.85e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL2—breast cancer	1.76e-07	1.85e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—breast cancer	1.75e-07	1.84e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KRAS—breast cancer	1.75e-07	1.84e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NCOA1—breast cancer	1.75e-07	1.84e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—HRAS—breast cancer	1.74e-07	1.83e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PIK3CA—breast cancer	1.74e-07	1.82e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—STAT3—breast cancer	1.73e-07	1.82e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SRC—breast cancer	1.73e-07	1.82e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—IL6—breast cancer	1.73e-07	1.82e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—breast cancer	1.73e-07	1.82e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—STK11—breast cancer	1.72e-07	1.81e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP19A1—breast cancer	1.72e-07	1.81e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KRAS—breast cancer	1.72e-07	1.81e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCND1—breast cancer	1.71e-07	1.8e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—JUN—breast cancer	1.71e-07	1.8e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CTNNB1—breast cancer	1.7e-07	1.78e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—breast cancer	1.69e-07	1.78e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—breast cancer	1.69e-07	1.77e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—NOS3—breast cancer	1.67e-07	1.76e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—STAT3—breast cancer	1.67e-07	1.76e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—HRAS—breast cancer	1.67e-07	1.75e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—IL6—breast cancer	1.67e-07	1.75e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—PIK3CA—breast cancer	1.67e-07	1.75e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—breast cancer	1.67e-07	1.75e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP9—breast cancer	1.66e-07	1.75e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CDKN1A—breast cancer	1.66e-07	1.74e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK3—breast cancer	1.66e-07	1.74e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PTEN—breast cancer	1.65e-07	1.74e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PIK3CA—breast cancer	1.64e-07	1.73e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK8—breast cancer	1.62e-07	1.7e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MYC—breast cancer	1.61e-07	1.69e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PIK3CA—breast cancer	1.61e-07	1.69e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TGFB1—breast cancer	1.61e-07	1.69e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—COMT—breast cancer	1.6e-07	1.69e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL6—breast cancer	1.6e-07	1.68e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK3—breast cancer	1.6e-07	1.68e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTP1—breast cancer	1.6e-07	1.68e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—breast cancer	1.6e-07	1.68e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—breast cancer	1.59e-07	1.67e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PIK3CA—breast cancer	1.58e-07	1.66e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HMOX1—breast cancer	1.57e-07	1.65e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ITPR1—breast cancer	1.57e-07	1.65e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—breast cancer	1.56e-07	1.64e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MYC—breast cancer	1.55e-07	1.63e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TGFB1—breast cancer	1.55e-07	1.63e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CB—breast cancer	1.55e-07	1.62e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—HRAS—breast cancer	1.54e-07	1.62e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—breast cancer	1.54e-07	1.62e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—breast cancer	1.53e-07	1.61e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—breast cancer	1.53e-07	1.61e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PIK3CA—breast cancer	1.53e-07	1.6e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HRAS—breast cancer	1.52e-07	1.6e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EGFR—breast cancer	1.52e-07	1.6e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ABCB1—breast cancer	1.51e-07	1.59e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—breast cancer	1.49e-07	1.57e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KRAS—breast cancer	1.49e-07	1.56e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HRAS—breast cancer	1.49e-07	1.56e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TYMS—breast cancer	1.48e-07	1.56e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—STAT3—breast cancer	1.48e-07	1.55e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—IL6—breast cancer	1.48e-07	1.55e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—breast cancer	1.47e-07	1.55e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NCOR1—breast cancer	1.47e-07	1.54e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.47e-07	1.54e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTM1—breast cancer	1.47e-07	1.54e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HRAS—breast cancer	1.46e-07	1.54e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL6—breast cancer	1.45e-07	1.53e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KRAS—breast cancer	1.43e-07	1.51e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6—breast cancer	1.42e-07	1.5e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—breast cancer	1.42e-07	1.49e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK3—breast cancer	1.41e-07	1.49e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GPX1—breast cancer	1.4e-07	1.48e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6—breast cancer	1.4e-07	1.47e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP1A1—breast cancer	1.39e-07	1.46e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ERCC2—breast cancer	1.38e-07	1.45e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MYC—breast cancer	1.37e-07	1.44e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TGFB1—breast cancer	1.37e-07	1.44e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CA—breast cancer	1.37e-07	1.44e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—breast cancer	1.36e-07	1.43e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EGFR—breast cancer	1.34e-07	1.41e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—breast cancer	1.34e-07	1.41e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTEN—breast cancer	1.34e-07	1.4e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—breast cancer	1.32e-07	1.39e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CA—breast cancer	1.32e-07	1.39e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—breast cancer	1.31e-07	1.38e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MTHFR—breast cancer	1.3e-07	1.36e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—breast cancer	1.29e-07	1.36e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—breast cancer	1.27e-07	1.34e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KRAS—breast cancer	1.27e-07	1.33e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HRAS—breast cancer	1.27e-07	1.33e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—breast cancer	1.25e-07	1.31e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HRAS—breast cancer	1.22e-07	1.28e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6—breast cancer	1.21e-07	1.27e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CAV1—breast cancer	1.2e-07	1.26e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6—breast cancer	1.17e-07	1.23e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CA—breast cancer	1.17e-07	1.23e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—breast cancer	1.13e-07	1.19e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—breast cancer	1.12e-07	1.17e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CG—breast cancer	1.09e-07	1.14e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HRAS—breast cancer	1.08e-07	1.13e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—breast cancer	1.08e-07	1.13e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6—breast cancer	1.03e-07	1.09e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CD—breast cancer	9.57e-08	1.01e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—breast cancer	9.53e-08	1e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALB—breast cancer	9.45e-08	9.93e-07	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CA—breast cancer	9.42e-08	9.9e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NOS3—breast cancer	9.04e-08	9.5e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CB—breast cancer	8.34e-08	8.77e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—breast cancer	8.27e-08	8.69e-07	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—breast cancer	7.7e-08	8.09e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTEN—breast cancer	7.21e-08	7.58e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CA—breast cancer	5.09e-08	5.35e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—breast cancer	4.15e-08	4.37e-07	CbGpPWpGaD
